Acknowledgements 2019nCoV-302 Study Group Members: The NVX-CoV2373-2019nCoV-302 clinical trial was a collective group effort across multiple institutions and locations. Below is a list of sites and staff that significantly contributed to the implementation and conduct of the NVX-CoV2373-2019nCoV-302 clinical trial.Peer reviewe

Baxter, David Neil

Bird, Olivia

Boffito,  Marta

Bradley, Judy M

Browne, Duncan

Burns, Fiona

Chadwick, David R.

Clark, Rebecca

Cosgrove, Catherine A

Galiza, Eva P.

Galloway, James

Goodman, Anna L.

Heath, Paul T

Heer, Amardeep

Higham, Andrew

Iyengar, Shalini

Jeanes, Christopher

Kalra, Philip

Kyriakidou,  Christina

McGill, Fiona

Minassian, Angela M.

Moore, Patrick

Munsoor, Imrozia

Munthali, Chigomezgo

Nicholls, Helen

Osanlou, Orod

Packham, Jonathan

Pretswell, Carol H.

San Francisco Ramos, Alberto

Saralaya, Dinesh

Sheridan, Ray P.

Smith, Richard

Soiza, Roy

Ster, Irina Chis

Swift, Pauline A.

Thomson, Emma C.

Turner, Jeremy

Viljoen, Marianne Elizabeth

Epidemiology and Infection

English

Aberdeen University Research

The predictive role of symptoms in COVID-19 diagnostic models : A longitudinal insight

To investigate the symptoms of SARS-CoV-2 infection, their dynamics and their discriminatory power for the disease using longitudinally, prospectively collected information reported at the time of their occurrence. We have analysed data from a large phase 3 clinical UK COVID-19 vaccine trial. The alpha variant was the predominant strain. Participants were assessed for SARS-CoV-2 infection via nasal/throat PCR at recruitment, vaccination appointments, and when symptomatic. Statistical techniques were implemented to infer estimates representative of the UK population, accounting for multiple symptomatic episodes associated with one individual. An optimal diagnostic model for SARS-CoV-2 infection was derived. The 4-month prevalence of SARS-CoV-2 was 2.1%; increasing to 19.4% (16.0%–22.7%) in participants reporting loss of appetite and 31.9% (27.1%–36.8%) in those with anosmia/ageusia. The model identified anosmia and/or ageusia, fever, congestion, and cough to be significantly associated with SARS-CoV-2 infection. Symptoms’ dynamics were vastly different in the two groups; after a slow start peaking later and lasting longer in PCR+ participants, whilst exhibiting a consistent decline in PCR- participants, with, on average, fewer than 3 days of symptoms reported. Anosmia/ageusia peaked late in confirmed SARS-CoV-2 infection (day 12), indicating a low discrimination power for early disease diagnosis.<br/

Boffito, Marta

Cosgrove, Catherine A.

Kalra, Philip A.

Kyriakidou, Christina

Bradley, Judy

Soiza, Roy L.

Viljoen, Marianne Elizabet

Heath, Paul T.

Chis Ster, Irina

Queen's University Belfast Research Portal

The predictive role of symptoms in COVID-19 diagnostic models: a longitudinal insight

https://aura.abdn.ac.uk/bitstream/2164/22913/1/Bird_etal_EI_The_Predictive_Role_VoR.pdf

The predictive role of symptoms in COVID-19 diagnostic models : A longitudinal insight

Abstract

Similar works

Full text

Available Versions

Aberdeen University Research

Queen's University Belfast Research Portal